Oculis Boosts Share Capital for Existing ATM Offering Program

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye disease treatments, has recently updated its share capital as part of its existing at-the-market (ATM) offering program. The company issued 2,500,000 new ordinary shares, each with a nominal value of CHF 0.01, bringing its total registered shares to 51,443,700. This move is part of Oculis' ongoing strategy to raise capital and fund its development programs in Diabetic Macular Edema and other ophthalmic indications.



The ATM offering program, established through a sales agreement with Leerink Partners LLC, allows Oculis to offer and sell ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The newly issued shares are recorded as treasury shares and will be held in reserve, providing Oculis with the flexibility to raise capital as needed.



The distribution of shares by Brunnur vaxtarsjóður slhf to its own shareholders on January 4, 2025, represents a significant change in Oculis' voting rights structure and ownership dynamics. This redistribution of shares indicates a shift in the company's ownership structure, although the specific details of the change are not explicitly stated in the provided material.

In conclusion, Oculis' update to its share capital for the existing ATM offering program demonstrates the company's commitment to raising capital and funding its development programs. The ATM offering program provides Oculis with the flexibility to raise funds as needed, supporting its financial strategy and growth. As the company continues to advance its pipeline of innovative product candidates, investors should keep a close eye on Oculis' progress and the potential impact on its share price.